These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 36542765)
21. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy. Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436 [TBL] [Abstract][Full Text] [Related]
22. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis. Mancuso-Stewart E; Rodger J; Zirwas M Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827 [TBL] [Abstract][Full Text] [Related]
23. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. Hu W; Thornton M; Livingston RA Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107 [TBL] [Abstract][Full Text] [Related]
24. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies. Bloudek L; Eichenfield LF; Silverberg JI; Joish VN; Lofland JH; Sun K; Augustin M; Migliaccio-Walle K; Sullivan SD Am J Clin Dermatol; 2023 Jan; 24(1):109-117. PubMed ID: 36264430 [TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699 [TBL] [Abstract][Full Text] [Related]
27. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Nakashima C; Yanagihara S; Otsuka A Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171 [TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. Kang C Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo. Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study. Naeimifar A; Ahmad Nasrollahi S; Samadi A; Aryanian Z; Akbari Javar H; Rouini M; Nassiri Kashani M; Firooz A J Dermatolog Treat; 2022 Dec; 33(8):3160-3164. PubMed ID: 35943737 [TBL] [Abstract][Full Text] [Related]
31. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice. Hussein AFA; Shams AS; Hosny N; Elrosasy A; Kobtan M; Shafik YA; Alnatsheh ZR; Zeid MA; Qarma M; Ibrahim YK; Al-Sultany HA Arch Dermatol Res; 2024 Aug; 316(8):518. PubMed ID: 39134884 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K; Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis. Zhang L; Du D; Wang L; Guo L; Jiang X J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567 [TBL] [Abstract][Full Text] [Related]
34. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Hebert AA Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454 [TBL] [Abstract][Full Text] [Related]
36. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Nezamololama N; Crowley EL; Gooderham MJ; Papp K Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227 [TBL] [Abstract][Full Text] [Related]
37. [Development of new topical substances for the treatment of atopic dermatitis]. Freimooser S; Traidl S; Werfel T Dermatologie (Heidelb); 2022 Jul; 73(7):514-519. PubMed ID: 35608634 [TBL] [Abstract][Full Text] [Related]
38. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Luger T; De Raeve L; Gelmetti C; Kakourou T; Katsarou A; Lambert J; Morren MA; Oranje A; Ruer M; Serdaroglu S; Torrelo A; Werfel T Eur J Dermatol; 2013; 23(6):758-66. PubMed ID: 24185493 [TBL] [Abstract][Full Text] [Related]
39. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039 [TBL] [Abstract][Full Text] [Related]